Streptococcus Pneumoniae Serotype 17F Conjugate Vaccine
This is a pneumococcal conjugate vaccine targeting Streptococcus pneumoniae serotype 17f. It uses CRM197 diphtheria protein as a carrier to enhance immunogenicity of the capsular polysaccharide antigen. Such vaccines work by stimulating the immune system to produce antibodies against the specific pneumococcal serotype included.
A pneumococcal conjugate vaccine using diphtheria protein carrier technology to induce immunity against S. pneumoniae serotype 17f.
Key facts at a glance
- RxNorm
- 2686919
- Generic
- Streptococcus Pneumoniae Serotype 17f Capsular Antigen Diphtheria Crm197 Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Capvaxive
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
This vaccine is designed to provide protection against infection by Streptococcus pneumoniae serotype 17f. Serotype 17f is among the numerous pneumococcal serotypes that can cause invasive pneumococcal disease, pneumonia, meningitis, and otitis media. Specific approved indications would depend on clinical trial data and regulatory approval status.
The vaccine contains capsular polysaccharides from serotype 17f that are chemically conjugated to CRM197, a nontoxic mutant of diphtheria toxin. This conjugation converts the T-cell independent polysaccharide antigen into a T-cell dependent antigen, enhancing immune response magnitude and generating immunological memory, particularly important for young children.
As a conjugate vaccine, it is expected to be suitable for pediatric populations where plain polysaccharide vaccines are less effective. Specific dosing, schedule, and safety profile would be established through clinical development. Vaccine effectiveness depends on prevalence of serotype 17f in the target population.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 31, 2026. · Read our editorial policy